Research on the hypoglycemic effects of Desugan liquid extract on experimental animals

Diabetes remains a prevalent chronic disease necessitating long-term management, yet conventional pharmacological treatments often present adverse side effects or lead to drug tolerance. Consequently, there is an increasing global interest in developing effective herbal diabetes drugs with improved safety profiles. Numerous individual medicinal herbs have demonstrated promising hypoglycemic effects; however, comprehensive evaluations of their synergistic combinations are limited. This study addresses this gap by investigating the hypoglycemic effects of Desugan liquid extract, a novel polyherbal formulation, in experimental animal models. Our objective is to determine its efficacy as a potential herbal medicine for diabetes management, thereby contributing to the development of safer therapeutic options.

Researchers in pharmacology, traditional medicine, and endocrinology, as well as healthcare professionals seeking evidence-based natural therapies for diabetes.

This study systematically investigated the hypoglycemic effects of Desugan liquid extract using two distinct experimental animal models to assess its potential as a herbal medicine for diabetes management. In the first model, rats orally administered with 10.5 g/kg glucose were treated with Desugan at doses of 3.15 g/kg/day and 9.45 g/kg/day for 14 days. Results showed a significant reduction in blood glucose levels compared to the control group (p<0.001), with reduction rates ranging from 23.22% to 32.96% across various time points after glucose administration. The higher dose of Desugan generally yielded better, though not statistically significant, reductions than the lower dose. In the second model, type 1 diabetic mice, induced by streptozotocin (STZ), received Desugan at 5.4 g/kg/day and 16.2 g/kg/day for 14 days. Here, Desugan remarkably reduced blood glucose levels compared to controls (p<0.001), with reduction rates ranging from 40.38% to 52.65%. Notably, the effects in STZ-induced mice were comparable to those of the reference drug insulin. While Desugan's efficacy in rats was less pronounced than acarbose, its overall performance in both models demonstrates its potent glucose tolerance improvement capabilities. These findings suggest that Desugan liquid extract holds significant promise as an effective therapeutic agent, warranting further clinical investigation for its application in managing both glucose-related imbalances and type 1 diabetes.